Recombinant Human NRG1/HRG1 Protein, CF
Recombinant Human NRG1/HRG1 Protein, CF Summary
Product Specifications
Ser20-Lys241, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
5898-NR
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute at 100 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Neuregulin-1/NRG1
Neuregulin-1 (NRG1) belongs to a family of structurally related glycoproteins encoded by four distinct but related genes, Nrg1, Nrg2, Nrg3, and Nrg4. Through alternative splicing or the use of alternative promoters, Nrg1 encodes more than 14 soluble or transmembrane proteins. Type I NRG1 isoforms include Neu Differentiation Factor, Heregulin, and ARIA. These consist of an N-terminal domain, an Ig-like domain, a linker with a Ser/Thr rich region, an EGF-like domain, a transmembrane segment, and a cytoplasmic domain. Type II isoforms such as Glial Growth Factor have a larger N-terminal domain and lack the Ser/Thr rich linker. Type III isoforms such as Sensory and Motor neuron-Derived Factor lack the Ig-like domain but contain a cysteine rich domain (CRD) and a second transmembrane segment (1 - 5). The alpha and beta splice variants of NRG1 differ in their extracellular juxtamembrane regions (3, 6). This recombinant protein corresponds to the extracellular domain (ECD) of the type I alpha isoforms (Accession # Q7RTV8). NRG1 isoforms exhibit distinct expression patterns and functions (7). The EGF-like domain, which is common to all NRG1 isoforms, is required for Neuregulin binding to ErbB3 or ErbB4 receptors (3). ErbB3 or ErbB4 subsequently heterodimerize with ErbB2, resulting in tyrosine phosphorylation and NRG1 induced signaling (1, 2). Soluble growth factors can be released by TACE/ADAM17, BACE, or ADAM19 mediated shedding of the ECD of transmembrane NRG1 (8 - 10). The cytoplasmic region can be cleaved by gamma -secretase, generating a repressor that inhibits the transcription of proapoptotic genes (11). NRG1 regulates multiple nervous system functions including axon guidance, synapse formation and plasticity, glial cell development, and axon myelination (1, 2). In the heart, NRG1 regulates organ morphogenesis and contractility and also plays a cardioprotective role following tissue injury (12). Multiple polymorphisms and aberrant expression of NRG1 isoforms are associated with the development of schizophrenia and many cancers (1, 2, 13).
- Mei, L. and W.-C. Xiong (2008) Nat. Rev. Neurosci. 9:437.
- Talmage, D.A. (2008) Novartis Found. Symp. 289:74.
- Holmes, W.E. et al. (1992) Science 256:1205.
- Marchionni, M.A. et al. (1993) Nature 362:312.
- Ho, W.-H. et al. (1995) J. Biol. Chem. 270:14523.
- Wen, D. et al. (1994) Mol. Cell. Biol. 14:1909.
- Meyer, D. et al. (1997) Development 124:3575.
- Hu, X. et al. (2006) Nat. Neurosci. 9:1520.
- Willem, M. et al. (2006) Science 314:664.
- Yokozeki, T. et al. (2007) Genes Cells 12:329.
- Bao, J. et al. (2003) J. Cell Biol. 161:1133.
- Lemmens, K. et al. (2007) Circulation 116:954.
- Breleux, M. (2007) Cell. Mol. Life Sci. 64:2358.
Citations for Recombinant Human NRG1/HRG1 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
24
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Glutamine metabolism prognostic index predicts tumour microenvironment characteristics and therapeutic efficacy in ovarian cancer
Authors: Gao, L;Wei, Z;Ying, F;Huang, L;Zhang, J;Sun, S;Wang, Z;Cai, J;Zhang, Y;
Journal of cellular and molecular medicine
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Prostaglandin D2 synthase controls Schwann cells metabolism
Authors: Trimarco, A;Audano, M;Marca, R;Cariello, M;Falco, M;Pedretti, S;Imperato, G;Cestaro, A;Podini, P;Dina, G;Quattrini, A;Massimino, L;Caruso, D;Mitro, N;Taveggia, C;
bioRxiv : the preprint server for biology
Species: Rat
Sample Types: Whole Cells
Applications: Bioassay -
Nuclear VANGL2 Inhibits Lactogenic Differentiation
Authors: Rubio, S;Molinuevo, R;Sanz?Gómez, N;Zomorrodinia, T;Cockrum, C;Luong, E;Rivas, L;Cadle, K;Menendez, J;Hinck, L;
Cells
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Fibroblast-derived EGF ligand Neuregulin-1 induces fetal-like reprogramming of the intestinal epithelium without supporting tumorigenic growth
Authors: TT Lemmetyine, EW Viitala, L Wartiovaar, T Kaprio, J Hagström, C Haglund, P Katajisto, TC Wang, E Domènech-M, S Ollila
Disease Models & Mechanisms, 2023-04-03;0(0):.
Species: Mouse
Sample Types: Organoid
Applications: Bioassay -
Neuregulin 1 (NRG1) modulates oocyte nuclear maturation during IVM and improves post-IVF embryo development
Authors: TT Dellaqua, RA Vígaro, LCZ Janini, M Dal Canto, MM Renzini, V Lodde, AM Luciano, J Buratini
Theriogenology, 2022-11-03;195(0):209-216.
Species: Bovine
Sample Types: Oocytes
Applications: Bioassay -
Cordycepin inhibits the proliferation of malignant peripheral nerve sheath tumor cells through the p53/Sp1/tubulin pathway
Authors: MJ Lee, JC Lee, JH Hsieh, MY Lin, IA Shih, HL You, K Wang
American journal of cancer research, 2021-04-15;11(4):1247-1266.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
Authors: Z Du, BP Brown, S Kim, D Ferguson, DC Pavlick, G Jayakumara, R Benayed, JN Gallant, YK Zhang, Y Yan, M Red-Brewer, SM Ali, AB Schrock, A Zehir, M Ladanyi, AW Smith, J Meiler, CM Lovly
Nature Communications, 2021-03-02;12(1):1382.
Species: Primate - Cercopithecus Aethiops
Sample Types: Whole Cells
Applications: Bioassay -
Mapping Development of the Human Intestinal Niche at Single-Cell Resolution
Authors: EM Holloway, M Czerwinski, YH Tsai, JH Wu, A Wu, CJ Childs, KD Walton, CW Sweet, Q Yu, I Glass, B Treutlein, JG Camp, JR Spence
Cell Stem Cell, 2020-12-04;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice
Authors: JS Lee, JY Lee, DW Song, HS Bae, HM Doo, HS Yu, KJ Lee, HK Kim, H Hwang, G Kwak, D Kim, S Kim, YB Hong, JM Lee, BO Choi
Nucleic Acids Res., 2020-01-10;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
Authors: TA Ahmed, C Adamopoulo, Z Karoulia, X Wu, R Sachidanan, SA Aaronson, PI Poulikakos
Cell Rep, 2019-01-02;26(1):65-78.e5.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response
Authors: JP Turowec, EWT Lau, X Wang, KR Brown, FA Fellouse, KK Jawanda, J Pan, J Moffat, S Sidhu
J. Biol. Chem., 2018-12-06;0(0):.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay -
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
Authors: T Osada, ZC Hartman, J Wei, G Lei, AC Hobeika, WR Gwin, MA Diniz, N Spector, TM Clay, W Chen, MA Morse, HK Lyerly
Breast Cancer Res., 2018-08-09;20(1):90.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation
Authors: G Del Monte-, M Ramialison, AAS Adam, B Wu, A Aharonov, G D'Uva, LM Bourke, ME Pitulescu, H Chen, JL de la Pomp, W Shou, RH Adams, SK Harten, E Tzahor, B Zhou, RP Harvey
Nature, 2018-05-09;0(0):.
Species: Mouse
Sample Types: Whole Tissue
Applications: Bioassay -
Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
Authors: LC Schmitt, A Rau, O Seifert, J Honer, M Hutt, S Schmid, J Zantow, M Hust, S Dübel, MA Olayioye, RE Kontermann
MAbs, 2017-04-19;0(0):0.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Ablation of neuropsin-neuregulin 1 signaling imbalances ErbB4 inhibitory networks and disrupts hippocampal gamma oscillation
Authors: M Kawata, S Morikawa, S Shiosaka, H Tamura
Transl Psychiatry, 2017-03-07;7(3):e1052.
Applications: Bioassay -
Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer
Authors: YC Xu, X Wang, Y Chen, SM Chen, XY Yang, YM Sun, MY Geng, J Ding, LH Meng
Theranostics, 2017-02-23;7(4):974-986.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis.
Authors: McElroy S, Castle S, Bernard J, Almohazey D, Hunter C, Bell B, Al Alam D, Wang L, Ford H, Frey M
Am J Pathol, 2014-09-09;184(10):2768-78.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Alveolar progenitor and stem cells in lung development, renewal and cancer.
Authors: Desai, Tushar J, Brownfield, Douglas, Krasnow, Mark A
Nature, 2014-02-05;507(7491):190-4.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.
Authors: Lee, Cleo Yi-, Lin, Yuan, Bratman, Scott V, Feng, Weiguo, Kuo, Angera H, Scheeren, Ferenc A, Engreitz, Jesse M, Varma, Sushama, West, Robert B, Diehn, Maximili
Cancer Res, 2013-10-31;74(1):341-52.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.
Authors: Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, Belzil V, Dion P, Higasa K, Doi K, Ishiura H, Mitsui J, Date H, Ahsan B, Matsukawa T, Ichikawa Y, Moritoyo T, Ikoma M, Hashimoto T, Kimura F, Murayama S, Onodera O, Nishizawa M, Yoshida M, Atsuta N, Sobue G, Fifita J, Williams K, Blair I, Nicholson G, Gonzalez-Perez P, Brown R, Nomoto M, Elenius K, Rouleau G, Fujiyama A, Morishita S, Goto J, Tsuji S
Am J Hum Genet, 2013-10-10;93(5):900-5.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
ErbB2 upregulates the Na+,HCO3(-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4.
Authors: Gorbatenko A, Olesen C, Morup N, Thiel G, Kallunki T, Valen E, Pedersen S
FASEB J, 2013-10-02;28(1):350-63.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src.
Authors: Ishibashi K, Fukumoto Y, Hasegawa H, Abe K, Kubota S, Aoyama K, Kubota S, Nakayama Y, Yamaguchi N
J Cell Sci, 2012-12-10;126(0):625-37.
Species: Human, Mouse, Primate - Chlorocebus aethiops (African Green Monkey)
Sample Types: Whole Cells
Applications: Bioassay -
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
Nature, 2012-07-26;487(7408):505-9.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Authors: Hickinson DM, Klinowska T, Speake G
Clin. Cancer Res., 2010-02-09;16(4):1159-69.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human NRG1/HRG1 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human NRG1/HRG1 Protein, CF and earn rewards!
Have you used Recombinant Human NRG1/HRG1 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image